Cash flow generation remains highly erratic, highlighted by a massive $14.4M working capital outflow in 2025Q4 and a 2026Q1 free cash flow burn of -$424.6K, indicating a lack of sustainable liquidity.
| Cash from Operations | -1.87M | -1.27M |
| Operating CF Margin % | - | -19.23% |
| Operating CF Growth % | -6195.83% | - |
| Net Income | -6.11M | 758.48K |
| Depreciation & Amortization | 347.45K | 353.1K |
| Stock-Based Compensation | 413.45K | 543.07K |
| Deferred Taxes | 0 | 0 |
| Other Non-Cash Items | 3.38M | -2.93M |
| Working Capital Changes | 87.88K | 0 |
| Change in Receivables | 136.13K | -3.8K |
| Change in Inventory | 122.96K | 53.85K |
| Change in Payables | -389.38K | -480.8K |
| Cash from Investing | -8.51K | -8.51K |
| Capital Expenditures | -8.51K | -8.51K |
| CapEx % of Revenue | 0.13% | 0.13% |
| Acquisitions | 0 | 0 |
| Investments | - | - |
| Other Investing | 0 | 0 |
| Cash from Financing | 2.74M | 3.8M |
| Debt Issued (Net) | 1.23K | 0 |
| Equity Issued (Net) | 0 | 0 |
| Dividends Paid | -155.92K | -78.87K |
| Share Repurchases | 0 | 0 |
| Other Financing | 2.9M | 3.87M |
| Net Change in Cash | -60.71M | 2.52M |
| Free Cash Flow | -1.88M | -1.28M |
| FCF Margin % | -28.21% | -19.36% |
| FCF Growth % | - | - |
| FCF per Share | -0.10 | -0.02 |
| FCF Conversion (FCF/Net Income) | 0.31x | -1.68x |
| Interest Paid | -16.3K | 0 |
| Taxes Paid | 0 | 0 |
Limited Operational Runway
As reported in financial statements, MEHA exhibits extreme volatility in cash conversion, highlighted by a 2025Q4 OCF/NI ratio of -62.78, which suggests that reported net income is frequently decoupled from the actual cash-generating capacity of the underlying medical device distribution and manufacturing operations.
The wide variance between net income and operating cash flow indicates that non-cash items or significant working capital swings are distorting the company's true economic performance. Investors should monitor whether this disconnect stems from aggressive revenue recognition or timing mismatches in government-tendered receivables, as the current trend suggests earnings may not be translating into sustainable liquidity.
Based on the provided quarterly data, MEHA's free cash flow trajectory remains highly unstable, swinging from a $51.6M inflow in 2025Q3 to a $53.5M outflow in 2025Q4, indicating that the company lacks a predictable mechanism for generating consistent cash to fund its ongoing operational requirements.
The extreme fluctuations in FCF margins suggest that the business is highly sensitive to lumpy contract cycles or inventory management issues rather than steady-state operations. This volatility complicates valuation efforts and implies that the company's cash position is subject to sudden, material shifts that could jeopardize its ability to meet short-term obligations.
According to recent SEC filings, MEHA experienced a massive $14.4M working capital outflow in 2025Q4, which directly offset the gains seen in previous quarters and underscores the company's vulnerability to inefficient collection cycles or sudden inventory build-ups within its regional distribution network.
The erratic nature of these working capital changes suggests that the company may be struggling to manage its cash conversion cycle effectively, potentially due to delayed payments from hospital clients or over-accumulation of medical device inventory. Such instability in working capital management warrants further investigation into the company's credit terms and the reliability of its accounts receivable.
Analysis of the cash flow statement reveals that MEHA's reported figures are significantly impacted by non-operating adjustments, including stock-based compensation and fluctuating depreciation, which mask the core cash burn occurring within the business as it attempts to scale its manufacturing and distribution footprint.
The presence of stock-based compensation alongside negative operating cash flows suggests that the company is relying on equity-based incentives to preserve cash, which may not be sustainable if the share price remains under pressure. Furthermore, the reliance on non-operating income to bolster net income suggests that the core business model is currently failing to cover its own operating expenses.
Quick answers to the most common questions about buying MEHA stock.
Functional Brands, Inc. Common Stock (MEHA) generated $-1.3M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Functional Brands, Inc. Common Stock (MEHA) reported negative free cash flow of $1.3M in 2025, indicating capital requirements exceeded cash from operations.
Functional Brands, Inc. Common Stock (MEHA) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Functional Brands, Inc. Common Stock (MEHA) returned $0.1M to shareholders via cash dividends. This shows the company's commitment to returning capital to its equity investors.